PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...
Life-altering call during pandemic turned Sara Pincott's world upside down. The Whig today introduces a monthly column by ...
Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...
Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...
Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.
First for Women on MSN11d
Early Signs of MS Can Include Overactive Bladder and Double VisionWith celebrities like Christina Applegate, Jamie-Lynn Sigler and Selma Blair opening up about their battles with multiple ...
Martin E. Sanders, M.D., Chief Executive Officer of Io Therapeutics stated “The ability of IRX4204 to inhibit and functionally repair brain demyelination, while also inhibiting microglia-mediated ...
Multiple sclerosis (MS) is a chronic condition affecting the central nervous system. Its symptoms range from mild and intermittent to severe and permanently damaging. There’s currently no cure ...
An investigational drug for multiple sclerosis from Io Therapeutics has ... of IRX4204 to inhibit and functionally repair brain demyelination opens opportunities for potentially reparative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback